美罗华治疗侵袭性B细胞淋巴瘤疗效观察  

The observation of the treatment efficacy of rituximab to aggressive B-cell lymphoma

作　　者：李德育[1,2] 刘振华[1,2] 陈峥[1,2] 陈静波[1,2] 郑建萍[1,2] 戴永美[1,2] 崔同建[1,2] 

机构地区：[1]福建医科大学省立临床学院 [2]福建省立医院肿瘤内科

出　　处：《药品评价》2012年第30期16-18,共3页Drug Evaluation

摘　　要：目的:探讨美罗华治疗侵袭性B细胞淋巴瘤的临床疗效及优越性。方法:回顾性分析我院78例侵袭性B细胞NHL患者治疗情况,其中39例为观察组采用美罗华联合CHOP化疗方案,39例为对照组采用CHOP化疗方案,观察两组近期疗效及不良反应情况,并进行对比分析。结果:观察组CR率和有效率(CR+PR)率分别为79.49%和92.31%,明显高于对照组的53.85%和64.10%,组间比较差异有统计学意义(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:含美罗华的联合化疗方案可提高侵袭性B细胞淋巴瘤治疗的临床疗效,且不会增加其不良反应,是目前侵袭性B细胞淋巴瘤治疗的一种较佳方案,值得临床推广应用。Objective： To investigate the clinical efficacy and superiority of rituximab to aggressive B-cell lymphoma.Methods： 78 cases with aggressive B-cell NHL patients were non-randomly divided into the observation group and the control group,with 39 cases in each group,the observation group received rituximab combined with CHOP chemotherapy,the control group were given CHOP chemotherapy,efficacy and toxicity situation were observed and comparatively analyzed.Results： The CR rate and efficiency（CR＋PR） rates were 79.49% and 92.31%,significantly higher than those of the control group,53.85% and 64.10%,which were significantly different（P0.05）;incidence of side effects of the two groups showed no significant difference（P0.05）.Conclusion： The combined chemotherapy containing rituximab can improve the clinical efficacy of aggressive B-cell lymphoma,without increasing its toxicity,which is a better program as the treatment of aggressive B-cell lymphoma,and worthy of clinical application.

关 键 词：美罗华 侵袭性B细胞淋巴瘤 不良反应 

分 类 号：R733.1[医药卫生—肿瘤]